Current clinical perspectives on myocardial angiogenesis

Area of Science:

• Cardiovascular Medicine
• Regenerative Medicine
• Molecular Therapy

Background:

• Current treatments for atherosclerotic coronary artery disease (CAD) and congestive heart failure (HF) include medication, surgery, and transplantation.
• A subset of patients with severe CAD and end-stage HF are ineligible for or do not benefit adequately from conventional therapies.
• Gene therapy represents a novel therapeutic avenue for these challenging patient populations.

Purpose of the Study:

• To review myocardial angiogenesis as a therapeutic strategy for patients with severe symptomatic CAD and end-stage HF.
• To explore the potential of therapeutic angiogenesis using growth factors and cell transplantation.

Main Methods:

• Review of current literature on gene therapy and myocardial angiogenesis for cardiovascular diseases.
• Discussion of therapeutic approaches involving growth factors and cell-based therapies.

Main Results:

• Gene therapy is emerging as a promising treatment for patients with severe CAD and HF.
• Myocardial angiogenesis, through growth factors or cell transplantation, is a key focus for therapeutic development.

Conclusions:

• Gene therapy, specifically myocardial angiogenesis, holds significant promise for patients with advanced cardiovascular disease unresponsive to standard treatments.
• Further investigation into growth factor and cell transplantation therapies is warranted to improve outcomes for patients with severe CAD and HF.